2026-10-19T01:05:40Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/120752026-10-18T20:27:01Zopenairedrivercom_ebyu_10000col_ebyu_10001

The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-AnalysisErgun, YakupAkagunduz, BaranKaracin, CengizTurker, SemaUcar, GokhanDisease-free survivalHER2-expressionOverall survivalPredictive factorTriple negative breast neoplasmBreast NeoplasmsFemaleHumansRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast Neoplasmsepidermal growth factor receptor 2adultcancer stagingcancer survivaldisease free survivalgene expressionhumanMantel Haenszel testmeta analysisneoadjuvant chemotherapyoutcome assessmentprotein expressionprotein functionremissionReviewrisk factorsystematic reviewtriple negative breast cancerThis meta-analysis conducted a comprehensive analysis of research investigating the correlation between HER2 expression levels and treatment outcomes in early-stage triple-negative breast cancer (TNBC) patients. We systematically searched major databases for studies published up to January 01, 2023. The data from various studies examined the relationship between HER2-zero and HER2-low tumors in terms of pathological complete response (pCR) rates, disease-free survival (DFS), and overall survival (OS) outcomes. The odds ratio (OR) and 95% confidence interval (CI) by the number of events were calculated using the Mantel-Haenszel method to analyze pCR. The hazard ratio and 95% CI were calculated using the inverse variance method for DFS and OS. In all comparisons, I2 was 0% and no heterogeneity was detected. A total of 12 retrospective studies involving 4094 patients were included. Thirty-six percent of the patients were in the HER2-low group. All 12 studies were included in the pooled analysis for pCR, and there was no difference between HER2-zero and HER2-low (40% vs. 38%, respectively; pooled OR:1.01 95% CI 0.88-1.16; I2: 0%). Four studies were included in the pooled analysis for DFS and 3 in the OS analysis. DFS and OS were significantly better in the HER2-low group (pooled hazard ratio: 0.67 for DFS, 0.64 for OS). There was no difference between HER2-low and HER2-zero in terms of pCR in early-stage TNBC. However, HER2-low was found to be associated with prolonged DFS and OS. PROSPERO registration number: CRD42023391002 © 2023 Elsevier Inc.Elsevier Inc.2023Review Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12075https://doi.org/10.1016/j.clbc.2023.05.0151526-8209enClinical Breast Cancerinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/reviewhttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12075